In a major policy reinforcement, our Ministry of Health has reaffirmed its commitment to the global agenda of how Indonesia targets Cervical Cancer elimination by the year 2030.
During a high-level forum in Jakarta, Vice Minister of Health Prof. Dante Saksono Harbuwono emphasized that this vision is a critical mission to protect Indonesian women and the nation’s future generations.
As cervical cancer remains the second most prevalent cancer among women in Indonesia, the government is shifting toward a systemic, integrated solution to address the high mortality rates currently facing the country.
1. Addressing the Crisis: The Reality of Late Diagnosis
The urgency behind the 2030 elimination goal is underscored by current health statistics:
- Late-Stage Prevalence: Approximately 70% of new cervical cancer cases in Indonesia are diagnosed at an advanced stage.
- High Mortality: Nearly 50% of those diagnosed with the disease lose their lives.
- Systemic Impact: The Ministry views cervical cancer not merely as a medical issue but as a systemic challenge that affects mothers, wives, and daughters who hold vital roles in the family and the nation.
Read also: The Future of Healthcare: Navigating Medical Device Regulatory Services in Indonesia in 2026
2. The National Roadmap (2023–2030)
Indonesia’s strategy is aligned with the World Health Assembly’s global mandate.
- National Action Plan: The government has established the National Action Plan for the Elimination of Cervical Cancer 2023–2030 as a long-term roadmap.
- Integrated Care: The strategy focuses on integrating screening into the Primary Healthcare Integration (ILP) framework, ensuring services are accessible at the grassroots level.
3. Pilot Study Success: DNA HPV in East Java
A successful pilot study in East Java, supported by collaborators such as Jhpiego, Roche， 和 Biofarma, has provided a critical “snapshot” of the country’s readiness.
- Facility Readiness: The study evaluated the effectiveness of DNA HPV screening strategies and the readiness of local healthcare facilities.
- Strategic Recommendations: The findings will lead to improvements in healthcare seeking behavior, facility governance, and the capacity of healthcare human resources.
- DNA HPV Integration: This pilot supports the wider implementation of DNA HPV testing as a more accurate alternative to traditional methods.
4. Inclusive Partnerships and Cross-Sectoral Collaboration
The Ministry of Health emphasizes that elimination cannot be achieved by the government alone.
- Strategic Partnerships: The government is actively encouraging inclusive partnerships with the private sector and international organizations.
- Empowering Communities: Future programs will focus heavily on community empowerment to break down barriers to access.
Strategic Insight for Biotech & Diagnostic Investors
The government’s focus on DNA HPV screening and the successful pilot with major industry players like Roche and Biofarma indicates a clear regulatory and commercial pathway for molecular diagnostic tools.
Indonesia targets cervical cancer elimination represents one of the most significant public health commitments in Southeast Asia.
The national infrastructure being built around DNA HPV screening, integrated primary care, and cross-sectoral partnerships is creating a durable and expanding market for properly registered diagnostic technology.
For foreign medical device manufacturers, distributors, and healthcare companies expanding into Southeast Asia, the message is clear: medical device registration in Indonesia is the essential first step.
Without BPOM authorization, no product can legally participate in the supply chain supporting this national program. With it, manufacturers gain access to one of the most active and policy-supported healthcare procurement pipelines in the region.
Whether a company is entering the Indonesia HPV testing market for the first time or looking to expand an existing portfolio to include cervical cancer screening tools, the path begins with understanding and completing the BPOM registration process.
Expert guidance, early preparation, and a reliable local partner make all the difference between a delayed entry and a successfully positioned product.
